News

Evenity is a bone-building humanized monoclonal antibody developed to inhibit the activity of sclerostin. It is claimed to be the only bone builder that simultaneously increases bone formation

The collaboration will leverage both companies’ scientific and technological expertise and will build on Alnylam’s recent preclinical data showing potent and highly durable delivery of RNAi therapeutics to

Delivering an inhaled Dry Powder formulation of Aspirin directly into the deep sites of the lung is a novel new approach to lung cancer treatment. This new treatment

The approval has been granted for a complete, once-daily, single-tablet regimen of dolutegravir (DTG) 50mg and lamivudine (3TC) 300mg to treat HIV-1 infection in adults with no antiretroviral

Under the terms of the partnership, South Korea-based Celltrion will undertake manufacturing and supply of four recombinant antibodies to iProgen. Among the four antibodies, two will be targeting

INFUGEM, the first chemotherapy product that comes in a premixed, ready-to-infuse formulation, was approved by the U.S. Food and Drug Administration (FDA) in July 2018 in combination with

The material collaboration terms for patisiran, vutrisiran, and fitusiran, as previously announced, will continue unchanged. “Our landmark 2014 rare disease alliance with Sanofi resulted in the advancement of

The company has submitted a supplemental new drug application (sNDA) to the FDA for Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg tablets) for PrEP to reduce

The US Department of Justice (DOJ) alleged that the three pharmaceutical firms have violated the False Claims Act by illegally paying the Medicare or Civilian Health and Medical